Comparing Long-Course Chemoradiation With Short-Course Radiation Therapy in Rectal Cancer
Early results from the Polish II study showed a significant improvement in OS for preoperative short-course RT/chemotherapy compared with long-term chemo-RT.
Colorectal Cancer
Tumors With High Levels of Microsatellite Instability Responded Well to Treatment With PD-1 Inhibitors
New research has linked microsatellite instability and the number of insertion/deletion mutations present in a tumor to clinical response to checkpoint inhibition.
Incidence of Early-Onset Colon and Rectal Cancers Highest in Southern US States but Rising Fastest in Western US States
The incidence of early onset colorectal cancer per 100,000 people increased from 6.7 during 1995-1996 to 11.5 during 2014-2015 for residents of the state of WA.
Sequential Exposure to FOLFOXIRI Plus Bevacizumab Shows Benefit in Unresectable mCRC
The reintroduction of FOLFOXIRI/bev in the progressive setting may provide a further benefit in mCRC.
Frontline FOLFOXIRI Plus Bevacizumab Improved PFS in mCRC: Phase 3 Trial Results
The VISNU-1 trial is “the first study performed in a population selected by baseline [circulating tumor cell] count,” according to lead study author Javier Sastre, MD, PhD.
Update from AACR: Divergent Data on FLT3 Inhibitors Tell a Tale of 2 Outcomes in AML and mCRC
Several preclinical studies provided more refined and nuanced insights into the target itself, and bioinformatics uncovered a way to measure low levels of residual disease during morphologic remission.
Statin Use With Colorectal Cancer Lowers Risk for Early Death
Use of statins before or after colorectal cancer (CRC) diagnosis is linked to a lower risk for premature death, from either cancer or other causes.
Colorectal Cancer Incidence Increasing in Younger Adults
Colorectal cancer incidence is increasing among young adults in certain high-income countries.
Postsurgical ctDNA Levels May Predict Disease Recurrence in Colorectal Cancer
None of the 45 patients who had a negative postoperative ctDNA value experienced a relapse after a median follow-up of 49 months.
Oral Aspirin Does Not Up FIT Test Sensitivity for ID’ing CRC
Administration of a single dose of oral aspirin prior to fecal immunochemical testing does not increase test sensitivity for detecting advanced colorectal neoplasms.
Next post in Gastrointestinal Cancers
